An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.

Jinglei HuJing XuMuqiao YuYongchao GaoRong LiuHonghao ZhouWei Zhang

Published in: Journal of translational medicine (2020)

This integrated model has a better predictive capability to ascertain the prognosis of DLBCL patients prior to CHOP-like treatment, which may improve the clinical management of DLBCL patients and provide theoretical basis for individualized treatment.

Keyphrases

diffuse large b cell lymphoma
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
healthcare
epstein barr virus
squamous cell carcinoma
gene expression
radiation therapy
social media
copy number
clinical decision support